These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 27228974

  • 1. Human Basic Fibroblast Growth Factor Inhibits Tau Phosphorylation via the PI3K/Akt-GSK3β Signaling Pathway in a 6-Hydroxydopamine-Induced Model of Parkinson's Disease.
    Yang PH, Zhu JX, Huang YD, Zhang XY, Lei P, Bush AI, Xiang Q, Su ZJ, Zhang QH.
    Neurodegener Dis; 2016; 16(5-6):357-69. PubMed ID: 27228974
    [Abstract] [Full Text] [Related]

  • 2. Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice.
    Chen L, Cheng L, Wei X, Yuan Z, Wu Y, Wang S, Ren Z, Liu X, Liu H.
    Neurochem Res; 2017 Apr; 42(4):1141-1150. PubMed ID: 28005221
    [Abstract] [Full Text] [Related]

  • 3. Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway.
    Yue P, Gao L, Wang X, Ding X, Teng J.
    Neurochem Res; 2017 May; 42(5):1366-1374. PubMed ID: 28247332
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway.
    Gong L, Zhang QL, Zhang N, Hua WY, Huang YX, Di PW, Huang T, Xu XS, Liu CF, Hu LF, Luo WF.
    J Neurochem; 2012 Dec; 123(5):876-85. PubMed ID: 23094836
    [Abstract] [Full Text] [Related]

  • 5. Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease.
    Zhang L, Huang L, Chen L, Hao D, Chen J.
    Toxicol Lett; 2013 Oct 24; 222(2):155-63. PubMed ID: 23911879
    [Abstract] [Full Text] [Related]

  • 6. Squamosamide derivative FLZ protected dopaminergic neuron by activating Akt signaling pathway in 6-OHDA-induced in vivo and in vitro Parkinson's disease models.
    Bao XQ, Kong XC, Kong LB, Wu LY, Sun H, Zhang D.
    Brain Res; 2014 Feb 14; 1547():49-57. PubMed ID: 24384139
    [Abstract] [Full Text] [Related]

  • 7. Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
    Chen WF, Wu L, Du ZR, Chen L, Xu AL, Chen XH, Teng JJ, Wong MS.
    Phytomedicine; 2017 Feb 15; 25():93-99. PubMed ID: 28190476
    [Abstract] [Full Text] [Related]

  • 8. IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.
    Ayadi AE, Zigmond MJ, Smith AD.
    Exp Brain Res; 2016 Jul 15; 234(7):1863-1873. PubMed ID: 26894890
    [Abstract] [Full Text] [Related]

  • 9. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM, Ortiz R, Dye S, Campbell RB, Amiji MM, Waszczak BL.
    Neuroscience; 2014 Aug 22; 274():11-23. PubMed ID: 24845869
    [Abstract] [Full Text] [Related]

  • 10. ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
    Singh S, Mishra A, Shukla S.
    Mol Neurobiol; 2016 Sep 22; 53(7):4286-301. PubMed ID: 26223802
    [Abstract] [Full Text] [Related]

  • 11. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S, Xu Y, Chen G, Ma K, Han C, Guo Z, Zhang Z, Ye K, Cao X.
    Neuropharmacology; 2015 Dec 22; 99():448-58. PubMed ID: 26282118
    [Abstract] [Full Text] [Related]

  • 12. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
    Voutilainen MH, De Lorenzo F, Stepanova P, Bäck S, Yu LY, Lindholm P, Pörsti E, Saarma M, Männistö PT, Tuominen RK.
    eNeuro; 2017 Dec 22; 4(1):. PubMed ID: 28303260
    [Abstract] [Full Text] [Related]

  • 13. Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway.
    Chu JM, Chen LW, Chan YS, Yung KK.
    Neuropharmacology; 2011 Dec 22; 61(8):1389-98. PubMed ID: 21907219
    [Abstract] [Full Text] [Related]

  • 14. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
    Pariyar R, Bastola T, Lee DH, Seo J.
    Int J Mol Sci; 2022 Feb 21; 23(4):. PubMed ID: 35216503
    [Abstract] [Full Text] [Related]

  • 15. Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease.
    Leikas JV, Kohtala S, Theilmann W, Jalkanen AJ, Forsberg MM, Rantamäki T.
    J Neurochem; 2017 Aug 21; 142(3):456-463. PubMed ID: 28488766
    [Abstract] [Full Text] [Related]

  • 16. A hypothetic role of minocycline as a neuroprotective agent against methylphenidate-induced neuronal mitochondrial dysfunction and tau protein hyper-phosphorylation: Possible role of PI3/Akt/GSK3β signaling pathway.
    Salehi P, Shahmirzadi ZY, Mirrezaei FS, Shirvani Boushehri F, Mayahi F, Songhori M, Abofazeli M, Motaghinejad M, Safari S.
    Med Hypotheses; 2019 Jul 21; 128():6-10. PubMed ID: 31203911
    [Abstract] [Full Text] [Related]

  • 17. Resveratrol delays 6-hydroxydopamine-induced apoptosis by activating the PI3K/Akt signaling pathway.
    Huang N, Zhang Y, Chen M, Jin H, Nie J, Luo Y, Zhou S, Shi J, Jin F.
    Exp Gerontol; 2019 Sep 21; 124():110653. PubMed ID: 31295526
    [Abstract] [Full Text] [Related]

  • 18. NMR-Based Metabolomics Reveal a Recovery from Metabolic Changes in the Striatum of 6-OHDA-Induced Rats Treated with Basic Fibroblast Growth Factor.
    Zheng H, Zhao L, Xia H, Xu C, Wang D, Liu K, Lin L, Li X, Yan Z, Gao H.
    Mol Neurobiol; 2016 Dec 21; 53(10):6690-6697. PubMed ID: 26650045
    [Abstract] [Full Text] [Related]

  • 19. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J, Sharma MK, Gengler S, Hölscher C.
    Neuropharmacology; 2017 May 01; 117():238-248. PubMed ID: 28223210
    [Abstract] [Full Text] [Related]

  • 20. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH, Fabricius K, Barkholt P, Mikkelsen JD, Jelsing J, Pyke C, Knudsen LB, Vrang N.
    Brain Res; 2016 Sep 01; 1646():354-365. PubMed ID: 27233809
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.